Vyvanse Sales Data
| Rank 27 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Vyvanse U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 27 ( 1) |
$430,909 | 5.48% | 814 | -2.75% |
| Q4 2012 | 28 (7) |
$408,526 | 11.92% | 837 | 11.75% |
| Q3 2012 | 35 (3) |
$365,023 | -2.81% | 749 | -2.60% |
| Q2 2012 | 38 (2) |
$375,563 | -3.00% | 769 | -2.78% |
| Q1 2012 | 40 (3) |
$387,167 | 11.05% | 791 | 4.08% |
| Q4 2011 | 43 (2) |
$348,645 | 13.05% | 760 | 13.26% |
| Q3 2011 | 45 ( 1) |
$308,386 | 1.08% | 671 | 1.51% |
| Q2 2011 | 44 (5) |
$305,102 | -1.39% | 661 | -1.49% |
| Q1 2011 | 49 | $309,394 |  |
671 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| November 15, 2010 | Vyvanse Approved for Adolescent ADHD |
